PG2 Injection 500 mg in Acute Stroke Study (Pass) "Pass"

Active, not recruiting

Phase 2 Results N/A

Summary of Purpose

The primary objective of this study is to evaluate the efficacy of PG2 Injection 500 mg versus placebo, administered intravenously within 3-6 hrs of stroke onset to patients with an acute ischemic stroke, as determined by Modified Rankin Scale (mRS) score at Day 90. The secondary objectives are as follows: - To evaluate the efficacy of PG2 Injection 500 mg versus placebo as determined by Barthel...

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 19 July 2015.

1 Jun 2012 20 May 2012 1 Oct 2015 1 Oct 2015 1 Jul 2015 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
  • Purpose: Treatment
  • Endpoint: Safety/Efficacy Study
  • Intervention: Parallel Assignment

Contacts